

# Liam O'Mahony

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9433888/publications.pdf>

Version: 2024-02-01

204  
papers

21,349  
citations

11651

70  
h-index

10734

138  
g-index

212  
all docs

212  
docs citations

212  
times ranked

22096  
citing authors

#	ARTICLE	IF	CITATIONS
1	Environment-dependent alterations of immune mediators in urban and rural South African children with atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 569-581.	5.7	14
2	The maternal diet index in pregnancy is associated with offspring allergic diseases: the Healthy Start study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 162-172.	5.7	45
3	EAACI Biologicals Guidelines "Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 17-38.	5.7	19
4	Cellular and molecular mechanisms of allergic asthma. Molecular Aspects of Medicine, 2022, 85, 100995.	6.4	71
5	Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: A systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1373-1388.	5.7	37
6	Higher levels of bacterial DNA in serum associate with severe and fatal COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1312-1314.	5.7	11
7	Microbiome-immune interactions and relationship to asthma severity. Journal of Allergy and Clinical Immunology, 2022, 149, 533-534.	2.9	8
8	Metabolic rewiring and serotonin depletion in patients with postacute sequelae of COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1623-1625.	5.7	11
9	Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2337-2354.	5.7	9
10	Allergy-related outcomes at 12 months in the CORAL birth cohort of Irish children born during the first COVID 19 lockdown. Pediatric Allergy and Immunology, 2022, 33, e13766.	2.6	17
11	Associations between child filaggrin mutations and maternal diet with the development of allergic diseases in children. Pediatric Allergy and Immunology, 2022, 33, e13753.	2.6	4
12	Parenting a newborn baby during the COVID-19 pandemic: a qualitative survey. BMJ Paediatrics Open, 2022, 6, e001348.	1.4	5
13	A high-risk gut microbiota configuration associates with fatal hyperinflammatory immune and metabolic responses to SARS-CoV-2. Gut Microbes, 2022, 14, 2073131.	9.8	40
14	Role of dietary fiber in promoting immune health "An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3185-3198.	5.7	48
15	Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 114-130.	5.7	40
16	EAACI Biologicals Guidelines "Recommendations for severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 14-44.	5.7	156
17	COVID-19 pandemic: Practical considerations on the organization of an allergy clinic "An EAACI/ARIA Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 648-676.	5.7	79
18	ARIA EAACI statement on asthma and COVID-19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 45-58.	5.7	41
20	Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 59-70.	5.7	58
21	Inhibition of CpG methylation improves the barrier integrity of bronchial epithelial cells in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1864-1868.	5.7	12
22	An Exopolysaccharide Produced by <i>Bifidobacterium longum</i> 35624 <sup>Å</sup> ® Inhibits Osteoclast Formation via a TLR2-Dependent Mechanism. <i>Calcified Tissue International</i> , 2021, 108, 654-666.	3.1	17
23	Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2337-2353.	5.7	78
24	EAACI guideline: Preventing the development of food allergy in infants and young children (2020) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50</i>	2.6	216
25	Immunonutrition: The importance of a new European Academy of Allergy and Clinical Immunology working group addressing a significant burden and unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2303-2305.	5.7	11
26	Gut microbial-derived short-chain fatty acids and bone: a potential role in fracture healing. , 2021, 41, 454-470.		19
27	Mechanisms of microbe-immune system dialogue within the skin. <i>Genes and Immunity</i> , 2021, 22, 276-288.	4.1	33
28	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1640-1660.	5.7	72
29	ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. <i>Clinical and Translational Allergy</i> , 2021, 11, e12014.	3.2	24
30	Long-term disruption of cytokine signalling networks is evident in patients who required hospitalization for SARS-CoV-2 infection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2910-2913.	5.7	20
31	ARIA-EAACI statement on severe allergic reactions to COVID-19 vaccines – An EAACI-ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1624-1628.	5.7	66
32	The impact of COVID-19 lockdown on infants' coronavirus exposure and routine healthcare access in Ireland: The CORAL birth cohort study at 6 months. <i>Pediatric Allergy and Immunology</i> , 2021, 32, 1876-1879.	2.6	9
33	Spermidine and spermine exert protective effects within the lung. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00837.	2.4	31
34	Dangerous liaisons: Bacteria, antimicrobial therapies, and allergic diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3276-3291.	5.7	9
35	IL-10 induces IgG4 production in NOD- <i>scid</i> mice humanized by engraftment of peripheral blood mononuclear cells. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3525-3529.	5.7	2
36	COVID-19 pandemic and allergen immunotherapy – an EAACI survey. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3504-3516.	5.7	26

#	ARTICLE	IF	CITATIONS
37	Fracture biomechanics influence local and systemic immune responses in a murine fracture-related infection model. <i>Biology Open</i> , 2021, 10, .	1.2	6
38	Examining Associations Between Dietary Inflammatory Index in Pregnancy, Pro-inflammatory Cytokine and Chemokine Levels at Birth, and Offspring Asthma and/or Wheeze by Age 4 Years. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2021, 121, 2003-2012.e3.	0.8	8
39	EAACI Biologicals Guidelinesâ€”dupilumab for children and adults with moderateâ€”toâ€”severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	5.7	24
40	Advanced glycation end product intake during pregnancy and offspring allergy outcomes: A Prospective cohort study. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1459-1470.	2.9	10
41	Early-Life Respiratory Infections in Infants with Cowâ€™s Milk Allergy: An Expert Opinion on the Available Evidence and Recommendations for Future Research. <i>Nutrients</i> , 2021, 13, 3795.	4.1	6
42	Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation. <i>Advances in Experimental Medicine and Biology</i> , 2021, , 119-133.	1.6	5
43	Butyrate Inhibits Osteoclast Activity In Vitro and Regulates Systemic Inflammation and Bone Healing in a Murine Osteotomy Model Compared to Antibiotic-Treated Mice. <i>Mediators of Inflammation</i> , 2021, 2021, 1-17.	3.0	17
44	An Irish National Diabetes in Pregnancy Audit: aiming for best outcomes for women with diabetes. <i>Diabetic Medicine</i> , 2020, 37, 2044-2049.	2.3	9
45	Overview of in vivo and ex vivo endpoints in murine food allergy models: Suitable for evaluation of the sensitizing capacity of novel proteins?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 289-301.	5.7	28
46	EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 497-523.	5.7	101
47	Reply to: Dietary diversity and childhood asthma â€”Dietary acid load, an additional nutritional variable to consider. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2423-2423.	5.7	1
48	Intranasal <i>Bifidobacterium longum</i> protects against viral-induced lung inflammation and injury in a murine model of lethal influenza infection. <i>EBioMedicine</i> , 2020, 60, 102981.	6.1	47
49	Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3039-3068.	5.7	127
50	Immune response to SARSâ€”CoVâ€”2 and mechanisms of immunopathological changes in COVIDâ€”19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1564-1581.	5.7	828
51	Dietary factors during pregnancy and atopic outcomes in childhood: A systematic review from the European Academy of Allergy and Clinical Immunology. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 889-912.	2.6	95
52	A compendium answering 150 questions on COVIDâ€”19 and SARSâ€”CoVâ€”2. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2503-2541.	5.7	95
53	COST Action â€”ImpARASâ€”TM: what have we learnt to improve food allergy risk assessment. A summary of a 4-year networking consortium. <i>Clinical and Translational Allergy</i> , 2020, 10, 13.	3.2	19
54	Distribution of ACE2, CD147, CD26, and other SARSâ€”CoVâ€”2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVIDâ€”19 risk factors. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2829-2845.	5.7	403

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelinesâ€”Recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1058-1068.	5.7	67
56	Intranasal corticosteroids in allergic rhinitis in COVIDâ€”19 infected patients: An ARIAâ€”EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2440-2444.	5.7	114
57	Immunology of COVIDâ€”19: Mechanisms, clinical outcome, diagnostics, and perspectivesâ€”A report of the European Academy of Allergy and Clinical Immunology (EAACI). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2445-2476.	5.7	132
58	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq0 0 0 rgBT /Overlock 10 recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	5.7	232
59	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines â€”recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1043-1057.	5.7	85
60	The frequency of CD4â”+â”CD25â”+ FoxP3â”+â”CD127â”~ cells in Bet v 1 contiguous overlapping peptide immunotherapy as a putative marker of efficacy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2685-2686.	5.7	3
61	EAACI Research and Outreach Committee: Improving standards and facilitating global collaboration through a Research Excellence Network. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1899-1901.	5.7	3
62	Shortâ€”chain fatty acids modulate mast cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1848-1849.	5.7	8
63	Handling of allergen immunotherapy in the COVIDâ€”19 pandemic: An ARIAâ€”EAACI statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1546-1554.	5.7	87
64	European Position Paper on Rhinosinusitis and Nasal Polyps 2020. <i>Rhinology</i> , 2020, 58, 1-464.	1.3	1,555
65	Anwendung von Biologika bei allergischen und Typ-2- entzÃ¼ndlichen Erkrankungen in der aktuellen COVID-19-Pandemie â€” ein Positionspapier von AeDA, DGAKI, GPA, A-GAI, LGAI, A-GP, ARIA und EAACI. <i>Allergologie</i> , 2020, 43, 255-271.	0.1	9
66	Exposure of Children to Rural Lifestyle Factors Associated With Protection Against Allergies Induces an Anti-Neu5Gc Antibody Response. <i>Frontiers in Immunology</i> , 2019, 10, 1628.	4.8	11
67	Recent developments and highlights in food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2355-2367.	5.7	66
68	Future research trends in understanding the mechanisms underlying allergic diseases for improved patient care. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2293-2311.	5.7	76
69	Prioritizing research challenges and funding for allergy and asthma and the need for translational researchâ€”The European Strategic Forum on Allergic Diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2064-2076.	5.7	39
70	EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1429-1444.	5.7	103
71	The importance of social networksâ€”An ecological and evolutionary framework to explain the role of microbes in the aetiology of allergy and asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2248-2251.	5.7	25
72	Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2190-2201.e9.	2.9	133

#	ARTICLE	IF	CITATIONS
73	Microbiome and skin biology. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 328-333.	2.3	57
74	Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. <i>Nature Communications</i> , 2019, 10, 5711.	12.8	141
75	Bacterial secretion of histamine within the gut influences immune responses within the lung. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 899-909.	5.7	58
76	AllergoOncology: Microbiota in allergy and cancer – A European Academy for Allergy and Clinical Immunology position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1037-1051.	5.7	17
77	Infection burden and immunological responses are equivalent for polymeric and metallic implant materials in vitro and in a murine model of fracture-related infection. <i>Journal of Biomedical Materials Research - Part B Applied Biomaterials</i> , 2019, 107, 1095-1106.	3.4	6
78	High levels of butyrate and propionate in early life are associated with protection against atopy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 799-809.	5.7	327
79	Much ado about Biologicals: <i>Highlights of the Master Class on Biologicals, Prague, 2018</i>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 837-840.	5.7	2
80	Critical Entry Points – Microbiome. , 2019, , 15-19.		0
81	EPOS2020: development strategy and goals for the latest European Position Paper on Rhinosinusitis. <i>Rhinology</i> , 2019, 57, 162-169.	1.3	32
82	Mechanisms of food allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 11-19.	2.9	212
83	Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 300-310.e11.	2.9	182
84	Exposure to nonmicrobial N-glycolylneuraminic acid protects farmers' children against airway inflammation and colitis. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 382-390.e7.	2.9	44
85	Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 837-850.	5.7	79
86	AllergoOncology: Opposite outcomes of immune tolerance in allergy and cancer. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 328-340.	5.7	54
87	<sc>EAACI</sc> Guidelines on allergen immunotherapy: IgE-mediated food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 799-815.	5.7	379
88	Recent developments and highlights in mechanisms of allergic diseases: Microbiome. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2314-2327.	5.7	90
89	Microbiome and asthma. <i>Asthma Research and Practice</i> , 2018, 4, 1.	2.4	117
90	Exopolysaccharide from <i>Bifidobacterium longum</i> subsp. <i>longum</i> 35624, modulates murine allergic airway responses. <i>Beneficial Microbes</i> , 2018, 9, 761-773.	2.4	35

#	ARTICLE	IF	CITATIONS
91	Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1133-1147.	5.7	315
92	The microbiome in allergic disease: Current understanding and future opportunities—2017 PRACTALL document of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1099-1110.	2.9	264
93	Altered fatty acid metabolism and reduced stearyl-coenzyme a desaturase activity in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1744-1752.	5.7	29
94	Histamine receptor 2 modifies iNKT cell activity within the inflamed lung. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1925-1935.	5.7	37
95	Mechanisms underlying induction of allergic sensitization by Pru p 3. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1398-1408.	2.9	38
96	Biology of the Microbiome 1. <i>Gastroenterology Clinics of North America</i> , 2017, 46, 19-35.	2.2	33
97	Immune regulation by histamine and histamine-secreting bacteria. <i>Current Opinion in Immunology</i> , 2017, 48, 108-113.	5.5	89
98	A wide diversity of bacteria from the human gut produces and degrades biogenic amines. <i>Microbial Ecology in Health and Disease</i> , 2017, 28, 1353881.	3.5	107
99	Pathogenic Mechanisms and Host Interactions in <i>Staphylococcus epidermidis</i> Device-Related Infection. <i>Frontiers in Microbiology</i> , 2017, 8, 1401.	3.5	149
100	Role of Regulatory Cells in Oral Tolerance. <i>Allergy, Asthma and Immunology Research</i> , 2017, 9, 107.	2.9	59
101	Rhinovirus triggers increased inflammasome activation in human bronchial epithelium in asthma. , 2017, , .		3
102	Influence of fracture stability on <i>Staphylococcus epidermidis</i> and <i>Staphylococcus aureus</i> infection in a murine femoral fracture model. , 2017, 34, 321-340.		17
103	Genome Analysis and Characterisation of the Exopolysaccharide Produced by <i>Bifidobacterium longum</i> subsp. <i>longum</i> 35624. , PLoS ONE, 2016, 11, e0162983.	2.5	76
104	Allergen immunotherapy for IgE-mediated food allergy: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 24.	3.2	17
105	Current challenges facing the assessment of the allergenic capacity of food allergens in animal models. <i>Clinical and Translational Allergy</i> , 2016, 6, 21.	3.2	46
106	Microbiome—Host Immune System Interactions. <i>Seminars in Liver Disease</i> , 2016, 36, 317-326.	3.6	21
107	Histamine-secreting microbes are increased in the gut of adult asthma patients. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1491-1494.e7.	2.9	109
108	Interleukins (from IL-1 to IL-38), interferons, transforming growth factor $\beta^2$ , and TNF- $\alpha$ : Receptors, functions, and roles in diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 984-1010.	2.9	612

#	ARTICLE	IF	CITATIONS
109	The Surface-Associated Exopolysaccharide of <i>Bifidobacterium longum</i> 35624 Plays an Essential Role in Dampening Host Proinflammatory Responses and Repressing Local T <sub>H</sub> 17 Responses. <i>Applied and Environmental Microbiology</i> , 2016, 82, 7185-7196.	3.1	126
110	Histamine Receptor 2 is Required to Suppress Innate Immune Responses to Bacterial Ligands in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1575-1586.	1.9	33
111	Potential Role of Gut Microbial Metabolites in Allergy Prevention in Children. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB389.	2.9	1
112	Global Allergy Forum and 3rd Davos Declaration 2015. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 588-592.	5.7	47
113	Consensus Communication on Early Peanut Introduction and Prevention of Peanut Allergy in High-Risk Infants. <i>Pediatric Dermatology</i> , 2016, 33, 103-106.	0.9	36
114	Innate mechanisms can predict successful allergy immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 559-561.	2.9	11
115	Monitoring immune responses in a mouse model of fracture fixation with and without <i>Staphylococcus aureus</i> osteomyelitis. <i>Bone</i> , 2016, 83, 82-92.	2.9	45
116	Host-microbiome interactions in health and disease. <i>Clinical Liver Disease</i> , 2015, 5, 142-144.	2.1	4
117	The use of animal models to discover immunological mechanisms underpinning sensitization to food allergens. <i>Drug Discovery Today: Disease Models</i> , 2015, 17-18, 63-69.	1.2	9
118	Influence of microbiome and diet on immune responses in food allergy models. <i>Drug Discovery Today: Disease Models</i> , 2015, 17-18, 71-80.	1.2	16
119	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1193-1195.	5.7	13
120	Human Dendritic Cell DC-SIGN and TLR-2 Mediate Complementary Immune Regulatory Activities in Response to <i>Lactobacillus rhamnosus</i> JB-1. <i>PLoS ONE</i> , 2015, 10, e0120261.	2.5	29
121	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 258-261.	2.9	162
122	Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 87-90.	1.0	26
123	Prebiotics, probiotics, synbiotics, and the immune system. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 153-158.	2.3	204
124	Intestinal dendritic cells. <i>Current Opinion in Gastroenterology</i> , 2015, 31, 98-103.	2.3	34
125	Consensus Communication on Early Peanut Introduction and the Prevention of Peanut Allergy in High-risk Infants. <i>Pediatrics</i> , 2015, 136, 600-604.	2.1	23
126	EAACI Food Allergy and Anaphylaxis Guidelines. Primary prevention of food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 590-601.	5.7	386

#	ARTICLE	IF	CITATIONS
127	Histamine and gut mucosal immune regulation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 273-281.	5.7	134
128	Primary prevention of food allergy in children and adults: systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 581-589.	5.7	168
129	Histamine receptor 2 is a key influence in immune responses to intestinal histamine-secreting microbes. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 744-746.e3.	2.9	62
130	Salmonella Adhesion, Invasion and Cellular Immune Responses Are Differentially Affected by Iron Concentrations in a Combined In Vitro Gut Fermentation-Cell Model. <i>PLoS ONE</i> , 2014, 9, e93549.	2.5	44
131	Bifidobacterium infantis suppression of Peyer's patch MIP-1 $\alpha$ and MIP-1 $\beta$ secretion during Salmonella infection correlates with increased local CD4+CD25+ T cell numbers. <i>Cellular Immunology</i> , 2013, 281, 134-140.	3.0	37
132	Histamine receptor 2 modifies dendritic cell responses to microbial ligands. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 194-204.e12.	2.9	102
133	Transport of p3 across gastrointestinal epithelium – an essential step towards the induction of food allergy?. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1374-1383.	2.9	54
134	<i>Bifidobacterium infantis</i> 35624 modulates host inflammatory processes beyond the gut. <i>Gut Microbes</i> , 2013, 4, 325-339.	9.8	342
135	Immunomodulation by <i>Bifidobacterium infantis</i> 35624 in the Murine Lamina Propria Requires Retinoic Acid-Dependent and Independent Mechanisms. <i>PLoS ONE</i> , 2013, 8, e62617.	2.5	76
136	Portrait of an immunoregulatory bifidobacterium. <i>Gut Microbes</i> , 2012, 3, 261-266.	9.8	104
137	<i>Bifidobacterium infantis</i> 35624 administration induces Foxp3 T regulatory cells in human peripheral blood: potential role for myeloid and plasmacytoid dendritic cells. <i>Gut</i> , 2012, 61, 354-366.	12.1	242
138	<i>Bifidobacterium infantis</i> 35624 Protects Against Salmonella -Induced Reductions in Digestive Enzyme Activity in Mice by Attenuation of the Host Inflammatory Response. <i>Clinical and Translational Gastroenterology</i> , 2012, 3, e15.	2.5	40
139	Research needs in allergy: an EAACI position paper, in collaboration with EFA. <i>Clinical and Translational Allergy</i> , 2012, 2, 21.	3.2	127
140	Histamine regulation of innate and adaptive immunity. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 40.	3.0	38
141	Davos Declaration: Allergy as a global problem. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 141-143.	5.7	67
142	Microbiota and dietary interactions – an update to the hygiene hypothesis?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 451-461.	5.7	105
143	Interleukins, from 1 to 37, and interferon- $\gamma$ : Receptors, functions, and roles in diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 701-721.e70.	2.9	650
144	Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1612-1621.e8.	2.9	53

#	ARTICLE	IF	CITATIONS
145	The many routes of dendritic cells to ensure immune regulation. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1541-1542.	2.9	15
146	Regulation of the immune response and inflammation by histamine and histamine receptors. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 1153-1162.	2.9	254
147	Small Intestinal Bacterial Overgrowth in Nonalcoholic Steatohepatitis: Association with Toll-Like Receptor 4 Expression and Plasma Levels of Interleukin 8. <i>Digestive Diseases and Sciences</i> , 2011, 56, 1524-1534.	2.3	165
148	Immune system in the intestine and mucosal inflammation. <i>Clinical and Translational Allergy</i> , 2011, 1, .	3.2	0
149	Recombinant lactobacilli expressing linoleic acid isomerase can modulate the fatty acid composition of host adipose tissue in mice. <i>Microbiology (United Kingdom)</i> , 2011, 157, 609-615.	1.8	48
150	Impact of Administered <i>Bifidobacterium</i> on Murine Host Fatty Acid Composition. <i>Lipids</i> , 2010, 45, 429-436.	1.7	63
151	A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome. <i>Digestive Diseases and Sciences</i> , 2010, 55, 392-397.	2.3	228
152	<i>Bifidobacterium animalis</i> AHC7 protects against pathogen-induced NF- $\kappa$ B activation in vivo. <i>BMC Immunology</i> , 2010, 11, 63.	2.2	33
153	<i>Mycobacterium avium</i> subsp. <i>Paratuberculosis</i> (MAP) as a modifying factor in Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2010, 16, 296-304.	1.9	43
154	Bacterial strain-specific induction of Foxp3 <sup>+</sup> T regulatory cells is protective in murine allergy models. <i>Clinical and Experimental Allergy</i> , 2010, 40, 811-819.	2.9	189
155	Technical Advance: Function and efficacy of an $\alpha$ 4-integrin antagonist using bioluminescence imaging to detect leukocyte trafficking in murine experimental colitis. <i>Journal of Leukocyte Biology</i> , 2010, 88, 1271-1278.	3.3	14
156	Irritable Bowel Syndrome—Type Symptoms in Patients With Inflammatory Bowel Disease: A Real Association or Reflection of Occult Inflammation?. <i>American Journal of Gastroenterology</i> , 2010, 105, 1789-1794.	0.4	204
157	Novel immunotherapeutic approaches for allergy and asthma. <i>Autoimmunity</i> , 2010, 43, 493-503.	2.6	14
158	Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. <i>American Journal of Clinical Nutrition</i> , 2009, 89, 1393-1401.	4.7	162
159	Loss of vagal anti-inflammatory effect: in vivo visualization and adoptive transfer. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2009, 297, R1118-R1126.	1.8	84
160	Modulation of pathogen-induced CCL20 secretion from HT-29 human intestinal epithelial cells by commensal bacteria. <i>BMC Immunology</i> , 2009, 10, 54.	2.2	50
161	Metabolic activity of probiotics—Oxalate degradation. <i>Veterinary Microbiology</i> , 2009, 136, 100-107.	1.9	43
162	Portrait of a canine probiotic <i>Bifidobacterium</i> —From gut to gut. <i>Veterinary Microbiology</i> , 2009, 139, 106-112.	1.9	38

#	ARTICLE	IF	CITATIONS
163	Involvement of T helper type 17 and regulatory T cell activity in <i>Citrobacter rodentium</i> invasion and inflammatory damage. <i>Clinical and Experimental Immunology</i> , 2009, 157, 148-154.	2.6	55
164	Influence of the Gut Microbiota with Ageing. , 2009, , 153-173.		1
165	Clinical benefits of probiotic canine-derived <i>Bifidobacterium animalis</i> strain AHC7 in dogs with acute idiopathic diarrhea. <i>Veterinary Therapeutics: Research in Applied Veterinary Medicine</i> , 2009, 10, 121-30.	0.3	18
166	Effects of <i>Lactobacillus salivarius</i> 433118 on Intestinal Inflammation, Immunity Status and In Vitro Colon Function in Two Mouse Models of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2495-2506.	2.3	40
167	43 The Role of T Cells in Vagal Protection Against Intestinal Inflammation. <i>Gastroenterology</i> , 2008, 134, A-6.	1.3	1
168	Mucosal cytokine imbalance in irritable bowel syndrome. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1467-1476.	1.5	150
169	Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF- $\kappa$ B Activation. <i>PLoS Pathogens</i> , 2008, 4, e1000112.	4.7	315
170	Protective effects of <i>Lactobacillus reuteri</i> and <i>Bifidobacterium infantis</i> in murine models for colitis do not involve the vagus nerve. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2008, 295, R1131-R1137.	1.8	61
171	Probiotic Effects on Inflammatory Bowel Disease1,. <i>Journal of Nutrition</i> , 2007, 137, 819S-824S.	2.9	137
172	<i>Salmonella typhimurium</i> stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. <i>Clinical and Experimental Immunology</i> , 2007, 149, 109-116.	2.6	16
173	Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?. <i>Gastroenterology</i> , 2006, 130, 304-311.	1.3	544
174	Efficacy of an Encapsulated Probiotic <i>Bifidobacterium infantis</i> 35624 in Women with Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2006, 101, 1581-1590.	0.4	739
175	Differential cytokine response from dendritic cells to commensal and pathogenic bacteria in different lymphoid compartments in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2006, 290, C839-C845.	3.4	85
176	Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. <i>Clinical and Experimental Immunology</i> , 2006, 144, 273-280.	2.6	55
177	Functional modulation of human intestinal epithelial cell responses by <i>Bifidobacterium infantis</i> and <i>Lactobacillus salivarius</i> . <i>Immunology</i> , 2006, 118, 202-215.	4.4	248
178	Comparative and Functional Analysis of Sortase-Dependent Proteins in the Predicted Secretome of <i>Lactobacillus salivarius</i> UCC118. <i>Applied and Environmental Microbiology</i> , 2006, 72, 4143-4153.	3.1	145
179	Failure to Define What Constitutes a Patient Responder Is a Problem in the Interpretation of the Probiotic Clinical Trial Evaluating the Use of in Irritable Bowel Syndrome. <i>Gastroenterology</i> , 2005, 129, 772-772.	1.3	0
180	<i>Lactobacillus</i> and <i>bifidobacterium</i> in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles. <i>Gastroenterology</i> , 2005, 128, 541-551.	1.3	1,276

#	ARTICLE	IF	CITATIONS
181	Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. <i>Gut</i> , 2004, 53, 694-700.	12.1	170
182	Mechanisms of adherence of a probiotic <i>Lactobacillus</i> strain during and after in vivo assessment in ulcerative colitis patients. <i>Microbial Ecology in Health and Disease</i> , 2004, 16, 96-104.	3.5	19
183	Influence of bifidobacterium infantis feeding on secretagogue response and gut barrier function in rats recovering from colitis. <i>Gastroenterology</i> , 2003, 124, A311.	1.3	2
184	Differential cytokine response of cells derived from different lymphoid compartments to commensal and pathogenic bacteria. <i>Gastroenterology</i> , 2003, 124, A339.	1.3	0
185	Probiotics by the parenteral route-efficacy in murine colitis and arthritis. <i>Gastroenterology</i> , 2003, 124, A73.	1.3	0
186	Diversity of epithelial cell gene expression in response to different lactobacilli. <i>Gastroenterology</i> , 2003, 124, A93.	1.3	0
187	Plasticity of epithelial cell cytokine responses to commensal and pathogenic species. <i>Gastroenterology</i> , 2003, 124, A113.	1.3	0
188	Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. <i>Gut</i> , 2003, 52, 975-980.	12.1	399
189	A Randomised Controlled Trial of a Probiotic <i>Lactobacillus</i> Strain in Healthy Adults: Assessment of its Delivery, Transit and Influence on Microbial Flora and Enteric Immunity. <i>Microbial Ecology in Health and Disease</i> , 2002, 14, 81-89.	3.5	42
190	Sulfate-Reducing Bacteria Colonize Pouches Formed for Ulcerative Colitis but Not for Familial Adenomatous Polyposis. <i>Diseases of the Colon and Rectum</i> , 2002, 45, 384-388.	1.3	117
191	In vitro selection criteria for probiotic bacteria of human origin: correlation with in vivo findings. <i>American Journal of Clinical Nutrition</i> , 2001, 73, 386s-392s.	4.7	667
192	Assaying Interleukins Intracellularly by FACS. , 2001, , 041-048.		1
193	Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1219-1225.	3.7	255
194	Probiotic human bifidobacteria: Selection of a new strain and evaluation in vitro and in vivo. <i>Gastroenterology</i> , 2000, 118, A774.	1.3	6
195	Immunologic response to a novel probiotic organism in patients with active Crohn's disease. <i>Gastroenterology</i> , 2000, 118, A853.	1.3	4
196	Probiotics, mononuclear cells, and epithelial cells: An anti-inflammatory network. <i>Gastroenterology</i> , 2000, 118, A102.	1.3	5
197	Title is missing!. <i>Antonie Van Leeuwenhoek</i> , 1999, 76, 279-292.	1.7	320
198	Probiotics: from myth to reality. Demonstration of functionality in animal models of disease and in human clinical trials. <i>Antonie Van Leeuwenhoek</i> , 1999, 76, 279-92.	1.7	93

#	ARTICLE	IF	CITATIONS
199	Sylvester oâ€™halloran surgical scientific meeting. Irish Journal of Medical Science, 1998, 167, 1-16.	1.5	0
200	Effects of human recombinant growth hormone (rhGH) on inflammatory responses in patients undergoing abdominal aortic aneurysm repair. Intensive Care Medicine, 1998, 24, 128-131.	8.2	17
201	Quantitative intracellular cytokine measurement: ageâ€™related changes in proinflammatory cytokine production. Clinical and Experimental Immunology, 1998, 113, 213-219.	2.6	155
202	Functional Foods and Gastrointestinal Disorders. , 0, , 153-174.		0
203	Immunology of the Small Intestine. , 0, , 33-44.		0
204	Impact of Long COVID on health and quality of life. HRB Open Research, 0, 5, 31.	0.6	17